Arjuna Capital purchased a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 38,952 shares of the company's stock, valued at approximately $2,245,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of SNY. Angeles Investment Advisors LLC raised its position in shares of Sanofi by 1.9% during the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock worth $653,000 after purchasing an additional 210 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Sanofi by 27.6% during the 3rd quarter. Victory Capital Management Inc. now owns 8,669 shares of the company's stock worth $500,000 after purchasing an additional 1,876 shares during the last quarter. Keystone Financial Services grew its stake in Sanofi by 7.0% in the 3rd quarter. Keystone Financial Services now owns 13,605 shares of the company's stock worth $784,000 after acquiring an additional 892 shares during the period. Addison Advisors LLC grew its stake in Sanofi by 22.1% in the 3rd quarter. Addison Advisors LLC now owns 1,311 shares of the company's stock worth $76,000 after acquiring an additional 237 shares during the period. Finally, Catalytic Wealth RIA LLC grew its stake in Sanofi by 37.5% in the 3rd quarter. Catalytic Wealth RIA LLC now owns 12,853 shares of the company's stock worth $741,000 after acquiring an additional 3,503 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ SNY traded down $0.72 during trading on Wednesday, hitting $49.42. 152,406 shares of the company traded hands, compared to its average volume of 2,019,825. The company has a 50-day moving average price of $55.23 and a 200-day moving average price of $52.25. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 1 year low of $45.13 and a 1 year high of $58.97. The firm has a market capitalization of $125.42 billion, a P/E ratio of 25.58, a P/E/G ratio of 1.29 and a beta of 0.61.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. During the same period in the prior year, the company earned $2.55 EPS. The firm's revenue was up 12.3% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 4.27 EPS for the current year.
Several analysts have commented on SNY shares. Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Citigroup raised shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, StockNews.com cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $57.50.
Read Our Latest Stock Report on SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.